FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL					
OMB Number: 3235-010					
Estimated average b	urden				
hours per response:	0.5				

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Pomerantz Roger	2. Date of Even Requiring State (Month/Day/Yea 06/25/2015	ment	3. Issuer Name and Ticker or Trading Symbol Seres Therapeutics, Inc. [MCRB]							
(Last) (First) (Middle) C/O SERES THERAPEUTICS, INC.	4. Relationship of Report (Check all applicable) X Director		, , ,	Person(s) to Issuer 10% Owner		5. If Amendment, Date of Original Filed (Month/Day/Year)				
215 FIRST STREET			X Officer (give title below)	Other (spec below)		lividual or Joint/ cable Line)	Group Filing (Check			
(Street)			President and	X	X Form filed by One Reporting Person					
CAMBRIDGE MA 02142						Form filed by Reporting Pe	More than One erson			
(City) (State) (Zip)										
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownershi Form: Direct or Indirect (I (Instr. 5)	t (D) (Instr.	4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)				
Stock Option (right to buy)	(1)	11/06/2023	Common Stock	220,000	0.48	D				
Stock Option (right to buy)	(2)	08/07/2024	Common Stock	1,675,751	0.71	D				
Series B Convertible Preferred Stock	(3)	(3)	Common Stock	22,727	(3)	D				

Explanation of Responses:

- 1. The option vested as to 25% of the shares on September 9, 2014. The remainder of the shares vested or will vest in 12 equal quarterly installments thereafter.
- 2. The option vested as to 25% of the shares on June 1, 2015. The remainder of the shares vested or will vest in 12 equal quarterly installments thereafter.
- 3. The Series B Convertible Preferred Stock is convertible into Common Stock on a one-for-one basis and has no expiration date. Each share of Series B Convertible Preferred Stock will convert to Common Stock upon the listing of the issuer's securities on The NASDAQ Global Select Market.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

/s/ Eric D. Shaff, Attorney-in-06/25/2015

Fac

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, as of this 27th day of April, 2015, that the undersigned hereby constitutes and appoints the Chief Executive Officer of Seres Health, Inc. (the "Company"), who is currently Roger J. Pomerantz, and the Chief Financial Officer of the Company who is currently Eric D. Shaff, or either of them signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Seres Health, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to for me to fix your for all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date first written above.

/s/ Roger J. Pomerantz								
Signature								
Roger J. Pomerantz								
Printed Name								